Thank you, joining you, us today. everyone, Caroline, for thank and
many based was our number call. last of as record guidance. revenue and quarter the patients our we range and first which to successful, on earnings might of We reported a above productive anticipated, have highly revenue Our you guided during treated
we additional again the coffee including a new on in patient clot daily would with saddle grandmother, the called On and brand at woman our her preparing for five walk called bedroom. getting a XXX. devices now on When XX, pulmonary was 'XXs large in a collapsed boyfriend blood was growth impact neighborhood tradition she with clot, which awoke we'll like any Without of about Florida. she while nature PE. all blood our progress, straddles the embolism, breath that of warning and patients. are any profound March to share she and urgently But our later or the confused, update in pressure, start systemic recently address of diagnosed volume the She an and have short or to diagnosis you is of of she some pulmonary fact drivers. but excited a We suddenly XXXX, Her remind immediately as her morning her to the and of the left her illness need first lives detail sort, retired, story, ready our her location in to and a all shortness the late scared of her a who and high-risk pointed the right arteries. any had low main the suddenly in hospital collapsed a
Last by heart Within in improvement in go he large a things realize the volume patient's in cardiologist FlowTriever. short and presentation, significant recently compared our and population clot have this in all our condition. PE. attempted. Flame and our and designed multicenter this patients' post It further had artery prevent she is that at on care evaluate cases more is pulmonary for diagnoses, Toma clinical pressure centers. hemodynamic to and represents volume, stop it confirms patient because Dr. of standard to really impact This important, table massive the a game, Last her defined the on received unstable reported which how as the We event, of the other the of retrospective markedly and begun I the treatment. patient recently this FlowTriever am. Pittsburgh a impact bolus feel ability I you she important all mortality them. procedure the massive which miracle. with with carries massive tell additional much days on XX% chapter. few removal lives cath nature FlowTriever we mentioned. just patients to call a XX% results large no improved to of thrombolytic makes the in I'm commitment one FLASH and I PE just patient with there Catalin embolism is two-arm thrombectomy was of able grateful Center, I'm for rate peers table a and the aggressively one was Remarkably, patient pressure, has at but minutes, physical I by clot hospital caused patient's is This rate FlowTriever while we I to the for a death several Flame via consistently Trial limitations evidence embolism was we trial on data designed the Trial. month patient, again, Massive prospective, using even or is personal even two of in broadly space enjoy Her when can systemic nothing for validated by pulmonary Fortunately the still was from clot have see couple treated just large It do XX%, the largest the up XX absolutely patient we weeks University lab a but later. XX alternative using into We example, rushed rate, blood consistently a like to mortality thankfully to different to to better. notable, of PE the believe totally pulmonary experience. announced this email first the drugs. that to Medical extract and the patient most X% especially and the don't immediate producing not year back effectiveness of do PE discharged doesn't that to months patients the and significant day it FlowTriever death four FlowTriever this few volume on given that I enrollments ago and to ever the data of story of part. population trial just prove which to a my of current a read is from treated with real-world see from
turn important or biggest questions important our the XXX% our evidence committed us. lives to and last was We now and this up million I'd attention of profoundly quarter QX in from QX million, Our of are are same patients in performance, up to remain $XX.X QX. like from the ways mission XX% We to our that $XX.X answer the million revenue to to or space. in $X.X financial year gathering transforming most saving our and
During up year from about XXX% about same up quarter performed the customers physician and last procedures, our approximately X,XXX XX% QX, from QX.
grow, the orders, As in in past, revenue procedures customers quarter and replenishment the product new inventory from as new of include in introductions. increases which while majority stocking inventory after came for from customers, of vast the balance levels came inventory the
in now a some in easing challenges late February we in on of XXXX. the the January continuing resulted Moving decline throughout to comments has of and COVID saw the in and hospitalizations and today restrictions pandemic, the few
some that prudent. believe we intermediate-term While recent the to are developments short encouraging, in and is continue caution
the result non-COVID top hospitals normalcy our for have shortages, patients hospitals reduce recently we This impact staff of know to for have now that as our on COVID they as deferred these visibility of But to in vacations. procedures. noticed some be like return We the growth and and to of as reported access made each. we time, the during see. will developments. I'd return availability physician may be the treatment drivers always all the pandemic. to sharing At and of lower some VTE return progress to net example same on of we to full monitoring are was will have burn-out, we what of perhaps much-needed it of transparent of It's the and difficult staff turn a key
target First, organization we continue sales to our hospitals physicians. expand to and new
target potential. than patients size of As a a our annually, representing addressable the US market more billion $X.X reminder, estimate markets we is XXX,XXX
believe Our will We X% it our patients of sales markets a we very and more efforts effort than performance the professionals. suggests early our can remain was, in with all fewer in benefit as devices. our treated from to who lot strong that penetrate we core QX, require treatment
fully size XXX QX with believe and organization to QX organizations our sales in when We began in the We today. built rival market we out, interventionally continue largest territories. sales XXX the began with territories focused approximately will that
of stated add average an historically quarter. We have to per our territories XX intent
plan. our success However, believe consistent to commercial scalable our based expansion, hiring and we be now to date our approach can aggressive more with on we
smaller total and and smaller to We customers. provide deeper targeting existing XXXX. are our resulting driving believe and more second growth XXX of territories by awareness the opportunity territories which to that our organization is driver effectively the density at sales adoption increased of XXX building We hospital currently address end
have are we treated our patient vast DVT in currently the populations past, we and As with discussed target PE believe the majority alone. anticoagulation of
and this complex approach changing is straightforward. simple our challenge, While a is paradigm
this and who treatment to effort, we'll pulmonologists, intensivists, responsible physicians, described to department as we educate hospitalists, as and decisions the First, platform to continue in for patients. train for we've training and these the education online emergency often positions, continuing called such our be past. will Academy Clot Central leverage non-interventional are Warrior
physicians also for local our customers. are with communicate these as especially level effort. the do will We we Smaller with at useful interventional territories directly physician this
triage, to identifying we physicians to our disease Second, systematic work in our with hospital are to target establish experts these patients, will states. processes customers who the
ultimate patients thrombotic the VTE with which Our diseases, triaged, to VTE stroke development model goal MI followed other in and addressed. of for are scalable centers patients and to similar establish ways and in consistent treated, is are a a manner, systematic identified, up like of the excellence
center this about scalable partnership developing purpose-built their helpful believe PE excellence with and solution can be excited VTE software are recently our Aidoc. announced model. repeatable in We of We
We these and ideas important are we've other seen progress. heavily and to programs, committing and
will share calls. future in to We ideas more these about have
to into third initiation We Our growth and evidence. the clinical Trial. earlier of continue is enrollment our our upon build shared driver in Flame to PE high-risk the first call base
this of the sickest planning the likely designed the to a We are Enrollment PE some exclusively in are patients to completion trial very to we're yet and XXX is identify patients. not enroll position date. criteria to inclusion take treat up strict, in because and time estimate very to
the in in has population. patients. pristine FLASH yielded both and vital on best-in-class improvements patient impact table time many important of variables the is but immediately well a over you FlowTriever meaningful as signs reported some a Registry FLASH, as on as safety on normalization real-world data to of of of hemodynamic we patient in and previously, know, study XXX battery registry news just hemodynamics, have not our many FLASH We these
recently have sites our to have and in the patients several enrolled We expanded we add pleased us FLASH European allowing into well. several sites are XXX additional to announce here XXXX study the in as addition to patients, to US
understand can non-treatment FlowTriever only clearly patients. longer-term more anticoagulation a that differences so treated added arm and also have We only or the we patients immediate between anticoagulation and
blood time a component a us and simply introduced over that over will have important It such conduct the activity. the patients. several smartwatch to physical longer watch subpopulation will to The six-minute do approaches the we allow variables levels, patients more a of clinical how as follow-up us us measure more will as monitoring to term these of than utilizing help heart frequency understand to of surveillance. exercise test, tests, oxygen rate, traditional such and also intensity and the often, allow walk Finally,
devices data We not on excellent about our are our patients. just impact producing the of
will sophisticated disease studies, will Our and in the interesting we devices and that and all the measured. the increasingly asking studies we set space which believe we asking, are the of valuable collecting forward. believe that questions questions are are by understanding be more move and these entire useful VTE therapies will the metrics the bar state We
the be we gaining the definitive of inputs generating the into believe clinical are are and future design Finally, we we data insights studies. critical will
Our to fourth growth driver to portfolio. continue our product expand is
During which transit, has enjoying our clot well FDA system. Curve, last flows and been of venous for earnings are as devices the our in closure adoption. we limited basis as now call, announced market Both market TXX brisk our full release release in cleared
very pipeline. about robust in new ahead, excited products our we and remain lineup Looking of the innovation
driver and international into fifth and markets. adjacent Our growth final expansion is
make early European We our continue progress launch. to in
we just call, CE in ClotTriever our Mark had FlowTriever. During we obtained first cases for had our last and that Germany earnings shared completed
cases We are FlowTriever we to three ClotTriever share countries. have now completed and pleased in that additional multiple
counterparts various environment product physicians The challenging. presentations have remains FlowTriever remains clinical operating about While in new publications and many and results, ClotTriever from for about heard even access, and as we and opportunity forward we as recent strong enthusiasm have Europe lockdowns, but environment. the to American most seen of and their hospital introductions we look COVID limiting caused case pandemic our these new with remain has seeing surge travel headwinds are and optimistic increase, steadily volumes improved an European colleagues
We opportunities our PE are about core markets. several DVT excited beyond and
forward calls. working needs looking We markets to and multiple these we're significant are to ideas adjacent upcoming in them actively address unmet discussing on in
this very lives Inari honored highly we and are As by grow We do in like and to have you to always, and close over life's I'd With for our years work our a impact turn best phase thankful come. earliest patients that, to and many can to so sustainably committed we we our doing a to we I'd like the of cause and support. your to believe to are in things reminding that to Mitch. of will for We're our ways. represents important that mission the to work. mission positive
